Clinical Trial Update: Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

View source ↗

Summary

A registry evaluating long-term outcomes in patients undergoing Ga-68 PSMA-11 PET/CT imaging for prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ga-68 PSMA-11 radiotracer (Gallium-68 labeled PSMA-11 radiotracer)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Prostate Cancer (Adenocarcinoma) | Status: TERMINATED